Clinical Trial

Disease: Acute Myeloid Leukaemia, AML, (ISRCTN14430213)

Disease info:

Leukaemia is cancer of the white blood cells which are responsible for fighting infection. In leukaemia, the bone marrow produces abnormal levels of white blood cells. Acute myeloid leukaemia (AML) starts in the bone marrow but often quickly spreads into the bloodstream. AML sometimes spreads to other parts of the body such as the lymph nodes, liver, central nervous system and testicles. 

Commonly, AML develops from cells other than lymphocytes that would normally develop into white blood cells. The World Health Organization (WHO) divides AML into several subtypes based off genetic association. AML is also known as acute myelocytic leukaemia, acute myelogenous leukaemia, acute granulocytic leukaemia, and acute non-lymphocytic leukaemia.

 

Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy
Feb. 25, 2025

Unlock Premium CMN Content Today with a CMN+ Subscription

Already a CMN+ subscriber? Log in here

logo
Subscribe now

Subscribe to CMN+ and get access to premium CMN Content, CRISPRMED Recordings, Clinical Trial Database, Special offers ....

close
Search CRISPR Medicine